API
< Back to all clusters
[HEALTH] · Brazil · 3 sources

started · updated

Abbott to discontinue Depakote Sprinkle in Brazil

Abbott has announced the discontinuation of Depakote Sprinkle 125 mg in Brazil, a sodium valproate-based medication used to treat epilepsy in both adults and children. The decision has raised significant concerns among medical professionals and families.

Medical entities, including the Brazilian Society of Child Neurology (SBNI) and the Brazilian Epilepsy League (LBE), have expressed opposition to the move. They argue that no other medication currently on the market offers the same combination of low dosage, delayed release, and ease of administration. Unlike standard tablets or flavored syrups, the sprinkle format consists of micro-spheres that can be mixed with soft food without compromising the delayed-release mechanism. This feature is considered vital for patients with dysphagia, intellectual disabilities, or behavioral challenges.

Neurologists warn that switching to alternative forms, such as syrups or higher-dose tablets, may result in different blood concentration profiles and tolerability issues. While Anvisa requires manufacturers to maintain supply for 12 months following a discontinuation notice, families are already attempting to stockpile the medication to prevent treatment interruptions.

Entities

Abbott · Anvisa · Liga Brasileira de Epilepsia · Sociedade Brasileira de Neurologia Infantil